Washington, D.C. (August 3, 2017) – Today, the Biosimilars Forum issued the following statement on passage of the Food and Drug Administration Reauthorization Act (FDARA):
“The Biosimilars Forum applauds Senate passage of the FDA Reauthorization Act. This legislation provides the agency with the resources it needs to effectively and efficiently review applications and ultimately enable biosimilars to reach the patients waiting for them. The bill also improves management and accountability at FDA by putting in place programmatic and fiscal evaluation mechanisms.
“We urge President Trump to sign this into law immediately as passage of this reauthorization is an important step toward increasing access to lifesaving medicines for so many in need.”
About the Biosimilars Forum
The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.